Results 191 to 200 of about 999,068 (357)

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

Hepatology, EarlyView., 2022
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu, Bingqing Xu, Xiaodong Wang, Wen‐Hua Wan, Jinying Lu, Deyuan Kong, Yu Jin, Wenhua You, Hua Sun, Xiaoxin Mu, Dongju Feng, Yun Chen   +11 more
wiley   +1 more source

Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan: Are HBsAg and anti-HCV prerequisite screening parameters in tuberculosis control program?

, 2016
Muayad Aghali Merza, Safer M. Haji, Abid Mohialdeen Hasan Alsharafani, Shivan U. Muhammed   +3 more
openalex   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure. [PDF]

J Viral Hepat
Mohareb AM, Ezaz G, Kim AY, Freedberg KA, Boyd A, Hyle EP.   +5 more
europepmc   +1 more source

The efficacy of hepatitis B vaccine in Iranian population

, 2014
Arefeh Dehghani Tafti, Mehdi Tazhibi, Abdollah Hajivandi, Hossein Fallahzadeh   +3 more
openalex   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford, Nader Khalidi, Jason Springer, Marcia Friedman, Bernhard Hellmich, Christian Pagnoux, Natasha Dehghan, Ora Gewurz‐Singer, Curry L. Koening, Yih Chang Lin, Paul A. Monach, Larry W. Moreland, Aurore Fifi‐Mah, Oliver Flossmann, Lindsy J. Forbess, Peter Lanyon, Eamonn Molloy, Ulrich Specks, Robert Spiera, Elaine Yacyshyn, Carol A. McAlear, Cristina Burroughs, Rachel B. Jones, Rennie L. Rhee, Rula Hajj‐Ali, Kenneth J. Warrington, David Cuthbertson, Jeffrey P. Krischer, David Jayne, Peter A. Merkel, for the Vasculitis Clinical Research Consortium and the European Vasculitis Society, Eric Stratton, Marcin Trojanowski, Chris Zammitti, Jessica Ziemek, Javier Ache, Marianne Bernardo, Bryan Gonzalez, Mariko Ishimori, Bonnie Paul, Mahbuba Tusty, Swamy Venuturupalli, Daniel Wallace, Michael Weisman, Debora Bork, Tiffany Clark, Sonya Crook, Kathleen Gartner, Lori Strozniak, Elizabeth Kisela, Marcia Leon, Loretta Williams, Jeff Negrey, Hannah Thome, Andrew Wiecek, Beemnet Amdemicael, Emily Bakaj, Aliza Bloostein, Annel Fernandez, Chris Hatzis, Lindsay Lally, Misbah Baqir, Cynthia Beinhorn, Shannon Daley, Sue Donlinger, Samantha Fatis, Yeoniee Kim, Matthew Koslow, Matthew J. Koster, Kathleen Mieras, Tobias Peikert, Michael Stachowitz, Gwen E. Thompson, Medius Klinik Kirchheim, Nicole Hollinger, Nina Kempiners, Hartmut Mahrhofer, Anke Reichelt de Tenorio, Bastian Walz, Banita Aggarwal, Simon Carette, Nazrana Haq, Samyukta Jagadeesh, Suneet Khurana, Judy Vendramini, Amanda Butler, Mithun Chakravorty, Paige Draper, Cattleya Godsave, Marie‐Josèphe Pradère, Megan Rutter, Alan Thomas, Rebekah Alexander, Cong‐Qiu Chu, Daniela Ghetie, Amy Jeon, Michelle Jin, Kim Phung Nguyen, Brenda Olmos, Kelly Peel, Rosy Quinn, Cailin Sibley, Mayamol Joseph, Deepa Thapa, Sandra Messier, Diane Robins, Jayamarx Jayaraman, Kam Shojania, Richard Conway, Kathy Brickell, Phil Gallagher, Alison Clifford, Sylvia Gaucher, Ainslie Hildebrand, Karen Martins, Breanne Stewart, Stephen Chaudary, Namneet Sandhu, Stephen Williams, Karen Dahlsveen, Seerapani Gopaluni, Cecilia Matara, Mark McClure, Rona Smith, Amrita Bath, Leslie Glasco, Theresa Howard, Caitlin McMillian, Na Yu, Mingcai Zhang, Ruba Kado, Emily Lewis, W. Joseph McCune, Emily Siegwald, Jennifer Sylvester, Naomi Amudala, Kathryn Doyle, Matthew MacDonald, Leah Madden, Brian Rice, Antoine Sreih, Sally Thompson, Laurie Hope, Kimberly Liang, Douglas Lienesch, Niveditha Mohan, Kelly Reckley, John Carter, Gail Lewis, Michelle Orzechowski, Martha Finco, Jennifer Godina, Jessica Gonzalez, Julieanne Hall, Nereida Ortez, Gopi Penmetsa   +155 more
wiley   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Prevalence of occult hepatitis B infection and hepatitis B genotype characterization among blood donors in Jember Regency, East Java, Indonesia. [PDF]

BMC Infect Dis
Sugiharto VD, Hafza N, Muhammadiy NS, Riyanti R, Cao LC, Huyen DT, My TN, Huyen TTT, Song LH, Senjarini K, Velavan TP.   +10 more
europepmc   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source